Introduction
============

One devastating complication of exudative age-related macular degeneration is a retinal pigment epithelium (RPE) tear. In an RPE tear, the pigment epithelium sheath becomes separated from the neurosensoric retina. Although photoreceptor cells are not able to function during this separation,[@b1] they can survive up to 325 days after an RPE tear.[@b2] This knowledge is essential for planning therapies such as macular translocation[@b3] [@b4] or autologous pigment epithelium and choroid transplantation.[@b5] [@b6] These therapies are successful only in some cases but carry a high risk. Therefore, it is crucial to select patients who probably would benefit from surgery.

Some case reports on RPE tears reported spontaneous reattachments of the RPE using time-domain optical coherence tomography (OCT).[@b7] [@b8] In this study, we analyse the use of fundus autofluorescence (FAF) and spectral-domain optical coherence tomography (SD-OCT), which is superior to time-domain OCT, to enhance the current knowledge on remodelling process in RPE tears. If it is possible to predict this process, surgery would not be necessary for certain patients. In this paper, we examined the wound healing process of RPE tears to better understand which patients would have the greatest chance for such a reattachment.

Patients and methods
====================

A retrospective data analysis was conducted of patients at the University Eye Hospital of Cologne, Germany, from the year 2001 to 2011. Eighty-eight patients with RPE tears can be identified from this time period. Among these patients, 33 patients were included in the study; the rest of them not having FAF and SD-OCT images were excluded. In three patients (patients 1, 2 and 30) the acute event of RPE tear happened before the introduction of SD-OCT in our clinic in 2008 (approximately 1 year before); therefore, SD-OCT measurements were performed since 2008. Two eyes of two patients (patient 5 and the left eye of patient 9) were part of a microperimetric study reported before.[@b5] Approval from the local ethic committee was sought and waived due to the retrospective nature of the study. Informed consent was obtained from each patient after explanation of the nature and possible consequences of the study. The study followed the tenets of the Declaration of Helsinki.

Each patient underwent a routine ophthalmological examination, including best corrected visual acuity using Snellen charts, biomicroscopy and fluorescein and/or indocyanine green angiography. SD-OCT and FAF were performed at every visit.

SD-OCT was carried out with a Spectralis HRA+OCT device (Heidelberg Engineering, Heidelberg, Germany) that was equipped with an eye-tracking system for the simultaneous acquisition of near-infrared reflectance (λ=815 nm) and SD-OCT images. This simultaneous SD-OCT imaging was carried out with an illumination wavelength of 870 nm and an acquisition speed of 40 000 A-scans per second. For each eye, a standard protocol of SD-OCT imaging was used; this comprised a star of 6 B-scans (angle between scans was 30°) and a block containing 37 B-scans (20°×15°, distance between B-scans: 125 μm). For these purposes, 19 SD-OCT images were averaged to obtain the final image.

FAF was acquired using the same device (excitation at λ=488 nm, emission 500--700 nm). The field of view size encompassed 30°×30°, with an image resolution of 768×768 pixels.

Grading of RPE tear was performed using grading system as suggested by Sarraf *et al*.[@b9] According to this grading system, RPE tears are graded based on the greatest length of defect (hypofluorescent area in FAF) in the vector direction of the tear and foveal involvement. For this measurement, the FAF images at the first presentation of RPE tear were used because tear border was the easiest to be demarcated. Visual acuity was transformed into logarithm of the minimum angle of resolution (LogMAR).

Statistical analyses were done using PASW Statistics 18 (Predictive Analytics Software, V.18.0.0, IBM, Armonk, New York, USA). Demographic characteristics of the population are described with summary statistics, including frequency and percentage for categorical data. Continuous data are presented with mean ± SD or with median. Correlation between ordinal and interval data (as in between RPE tear grade and LogMAR BCVA) was performed using Spearman\'s rank order correlation coefficient. p Value \<0.05 was deemed as statistically significant.

Results
=======

In all, 36 eyes of 33 patients were identified as having RPE tears. Demographic characteristics of these patients are shown in [table 1](#tbl1){ref-type="table"}. Among 33 patients, 12 were men and 21 were women. The mean age was 76±8.3 (range 57--91) years old. The majority of patients (66.67%) had severe RPE tears, that is, grade 3 or 4 according to Sarraf *et al.* [@b9] In the follow-up time, change in RPE tears grade is observed only in one patient (2.8%), that is, a case of self-healing RPE tear presented below. In our findings, there was no correlation between RPE tears severity grade and LogMAR visual acuity at the first presentation (r~s~=0.102, p=0.553). Eighteen eyes (50%) received anti-vascular endothelial growth factor therapy prior to the RPE tear. Mean number of follow-up visits was 9.5±7.4 and median time after RPE tear was 325 days and median follow-up time was 969 days.

###### 

A summary of demographic characteristics

  Patient no.   Eye   RPE tear grade   Age   BCVA (LogMAR) at first visit   BCVA (LogMAR) at last visit   Therapy prior to RPE tear (no.)                  Time after RPE tears (d)   Total follow-up time (d)   FAF in RPE denuded area                       HRDs   Subretinal mass at last follow-up
  ------------- ----- ---------------- ----- ------------------------------ ----------------------------- ------------------------------------------------ -------------------------- -------------------------- --------------------------------------------- ------ -----------------------------------
  1             OS    2                86    0.35                           1.4                           Bevacizumab (1)                                  1938                       2092                       Dark                                          No     Yes
  2             OD    3                74    0.48                           1.5                           Bevacizumab (1)                                  1681                       1861                       Hazy hyperfluorescent                         Yes    No
  3             OS    3                90    1.30                           1.05                          None                                             882                        1911                       Dark, patchy hyperfluorescent on the border   No     Yes
  4             OD    3                77    0.4                            0.7                           Bevacizumab (4)                                  325                        329                        Dark                                          Yes    Yes
  5             OS    4                80    0.7                            1.3                           Ranibizumab (3)                                  330                        425                        Dark                                          No     No
  6             OD    3                76    1.3                            NA                            None                                             222                        1455                       Dark                                          Yes    Yes
  7             OS    4                73    0.45                           1.4                           None                                             212                        215                        Dark                                          Yes    No
  8             OD    2                70    0.15                           0.1                           None                                             1041                       1344                       Dark                                          Yes    No
  9             OD    3                72    0.45                           0.5                           None                                             372                        1302                       Dark                                          Yes    Yes
                OS    4                      0.5                            0.7                           Ranibizumab (3), Bevacizumab (1)                 226                        1302                       Patchy hyperfluorescent                       Yes    No
  10            OD    1                82    0.7                            1.5                           Ranibizumab (3)                                  732                        1671                       Dark                                          Yes    Yes
  11            OD    2                65    0.3                            1.5                           Ranibizumab (2)                                  52                         168                        Dark                                          Yes    No
  12            OD    3                85    0.56                           NA                            None                                             53                         54                         Dark                                          Yes    No
                OS    4                      0.2                            NA                            None                                             NA                         54                         Dark                                          Yes    No
  13            OS    2                80    0.55                           0.58                          Ranibizumab (3)                                  111                        455                        Dark                                          No     No
  14            OD    4                75    0.6                            0.2                           None                                             1165                       3405                       Patchy hyperfluorescent                       Yes    No
  15            OD    4                78    0.45                           NA                            Ranibizumab (2)                                  NA                         NA                         Dark                                          Yes    Yes
  16            OS    3                86    1                              1                             None                                             128                        337                        Dark                                          Yes    Yes
  17            OD    2                68    0.4                            0.4                           None                                             104                        1701                       Dark                                          Yes    Yes
  18            OS    2                62    0.3                            0.3                           None                                             109                        946                        Patchy hyperfluorescent                       Yes    Yes
  19            OD    3                81    1.30                           1.7                           Ranibizumab (3)                                  333                        1262                       Dark                                          Yes    No
  20            OD    4                83    1.3                            NA                            rtPA+SF6 (1), ranibizumab (1)                    NA                         819                        Dark                                          No     No
  21            OD    1                79    0.60                           0.1                           rtPA+SF6+bevacizumab (2)                         670                        925                        Dark                                          Yes    Yes
  22            OD    4                81    0.7                            1.5                           None                                             593                        1648                       Dark                                          Yes    No
                OS    4                      0.26                           1.3                           Ranibizumab (1)                                  32                         1648                       Dark                                          Yes    No
  23            OD    2                72    1                              1.4                           Ranibizumab (3)                                  77                         231                        Dark                                          No     No
  24            OS    3                91    0.6                            1.3                           Ranibizumab (3)                                  895                        992                        Dark                                          Yes    No
  25            OS    4                85    0.6                            NA                            Ranibizumab (2)                                  NA                         NA                         Dark                                          Yes    Yes
  26            OD    1                71    0.6                            0.6                           None                                             110                        2438                       Patchy hyperfluorescent                       Yes    No
  27            OS    1                83    0.8                            1                             None                                             663                        896                        Dark                                          Yes    Yes
  28            OD    4                61    0.3                            0.4                           None                                             317                        709                        Dark                                          Yes    Yes
  29            OD    4                57    0.7                            0.7                           None                                             158                        278                        Patchy hyperfluorescent                       Yes    No
  30            OS    4                68    0.3                            0.6                           Ranibizumab (3)                                  1334                       1996                       Dark                                          Yes    No
  31            OD    4                75    1.5                            1.5                           rtPA+SF6 (1), ranibizumab (5), bevacizumab (2)   NA                         810                        Dark                                          Yes    Yes
  32            OD    1                67    1                              NA                            None                                             NA                         NA                         Dark                                          Yes    No
  33            OD    4                72    0.2                            NA                            None                                             NA                         NA                         Dark                                          Yes    No

BCVA, best corrected visual acuity; d, days; FAF, fundus autofluorescence; HRDs, hyper-reflective dots; LogMAR, logarithm of the minimum angle of resolution; NA, not applicable; OD, the right eye; OS, the left eye; RPE, retinal pigment epithelium; rtPA, recombinant tissue plasminogen activator; SF6, sulphur hexafluoride 20%.

Subretinal blood was identified in 4 of 36 eyes (11.1%) at the first presentation. The peripheral torn edge of the RPE layer presented as a sharp border in recent RPE tears. Over time, these edges became hazier and could be less well demarcated. FAF of RPE tears showed a hypofluorescent area in the RPE denuded zone, indicating non-existing RPE. In 7 of 36 eyes (19.4%), hazy or speckled hyperfluorescent areas appeared in this region over time. The first hazy or speckled hyperfluorescent areas were seen approximately 3 months after the acute event of RPE tear. When correlated with SD-OCT, dots of hyper-reflective materials were visible in the retina. These hyper-reflective dots (HRDs) had various diameters ranging from 10 to 120 μm on SD-OCT images. Clumps of HRDs were arranged as chains in the posterior segment of the photoreceptor layer (POS) after the acute event of an RPE tear. These HRDs were present irrespective of the presence of subretinal or intraretinal fluid.

HRDs arranged around intraretinal cysts were mostly small in diameter (approximately 10 μm, presumably intraretinal hard exudates), while those located in the outer retinal layers were large (up to 120 μm) and showed a high backscattering effect. These large HRDs created a shadowing effect; presumably they represented migrating intraretinal RPE cells, if no intraretinal or subretinal fluid was present ([figure 1](#fig1){ref-type="fig"}). These HRDs were identified in 30 of 36 eyes (83.3%) on SD-OCT scans. They were frequently encountered in the outer retinal layers and sometimes in the inner retinal layers. Some HRDs in the RPE denuded area were located directly on Bruch\'s membrane. In FAF images, these migrating RPE cells appeared hyperfluorescent, while hard exudates appeared hypofluorescent ([figure 2](#fig2){ref-type="fig"}).

![A retinal pigment epithelium (RPE) tear 5 months after the acute event. Fundus autofluorescence (A) image showed patchy hyperfluorescent spots in the RPE denuded area. The corresponding spectral-domain optical coherence tomography (B) showed hyper-reflective dots (arrows). Shadowing effect posterior to the hyper-reflective dots can be seen.](bjophthalmol-2012-301750fig1){#fig1}

![A retinal pigment epithelium (RPE) tear 1 year and 2 months after the acute event. Fundus autofluorescence (A) image of retinal pigment epithelium tear showed hyperfluorescent spots in the RPE denuded area. The corresponding spectral-domain optical coherence tomography image (B) showed hyper-reflective dots (arrow), indicating intraretinal RPE migration.](bjophthalmol-2012-301750fig2){#fig2}

The border of the RPE denuded area presented as speckled hyperfluorescent areas in the FAF. In the corresponding SD-OCT, curled or redundant RPE layers were seen. Large HRDs with backscattering were frequently present in this region.

Overall, 15 of 36 eyes (41.7%) showed a homogenous subretinal mass in the RPE denuded area. These subretinal masses showed choroidal hyper-reflectivity as a sign of not having melanin to absorb light in the SD-OCT. The corresponding FAF images showed hypofluorescent area, indicating a lack of lipofuscin. These materials were in SD-OCT mostly homogenous and did not form a single layer ([figure 3](#fig3){ref-type="fig"}).

![A retinal pigment epithelium (RPE) tear 3 years after the acute event. Colour fundus photography (A) of RPE tear. The white star indicated the presence of intraretinal hard exudates, which appeared hypofluorescent in the corresponding fundus autofluorescence (B) image. The area between the two arrowheads (C) showed the enhanced choroidal hyper-reflectivity. A homogenous subretinal mass can also be seen. (D) The intraretinal hard exudates (star in A and B) are presented as a large hyper-reflective lesion with shadowing effect (white arrow). This figure is produced in colour in the online journal---please visit the website to view the colour figure.](bjophthalmol-2012-301750fig3){#fig3}

In 1 of 36 eyes (2.8%), the RPE tear was relatively small (patient 8). In follow-up visits, the defect in the RPE denuded area was covered with a layer of RPE cells. The hyper-reflective area indicated that the RPE denuded area constantly dissipated over time in the corresponding near infrared image. In SD-OCT, a new RPE layer was identified ([figure 4](#fig4){ref-type="fig"}). The corresponding FAF image in this area remained hypofluorescent, possibly indicating that this new RPE layer lacked lipofuscin.

![A case of self-healing retinal pigment epithelium (RPE) tear. The fundus autofluorescence (A) showed a small RPE defect, which corresponds to an area of enhanced choroidal hyper-reflectivity (B) (between arrowheads). Two and a half years after the RPE denuded area has been covered by a single RPE layer (C and D). The black star represents a small atrophy, used as an anatomical landmark, ensuring approximately the same level of SD-OCT measurements over time.](bjophthalmol-2012-301750fig4){#fig4}

Discussion
==========

Wound healing and RPE proliferation of RPE tears have been studied by several authors.[@b6] [@b10] In time domain OCT, the reattachment of the RPE layer and RPE repopulation have been documented.[@b7] We also found a considerable tissue remodelling over several years using FAF and SD-OCT. We saw RPE repopulation in one case, that is, a small RPE tear which is in line with other reports.[@b8] [@b10] These new RPE cells lacked lipofuscin, as shown in hypofluorescent FAF.

Histological studies of RPE tears also reported RPE cell migration and proliferation. In a case reported by Green *et al*, the RPE proliferated to the underside of the ripped basement membrane of the flap tear (cf, figure 15 in Green *et al*).[@b11] Although RPE proliferation might theoretically lead to a functional RPE layer, this proliferation is not directed.[@b11] In our study, we found misdirected RPE migration into the retina, which possibly did not lead to a functional RPE layer supporting the photoreceptors.

Intraretinal RPE cell migration has been described in various retinal diseases, for example, retinitis pigmentosa, congenital RPE hypertrophy[@b12] or early to late dry age-related macular degeneration.[@b13; @b14; @b15; @b16] In OCT images, migrating intraretinal RPE cells are hyper-reflective lesions with high backscattering and appear as hyperfluorescent areas in FAF. Other structures, such as hard exudates, may also appear as HRDs in SD-OCT,[@b17] but appear as hypofluorescent lesions in FAF ([figure 3](#fig3){ref-type="fig"}). The origin of migrated RPE cells seen in this study is unclear; there is a possibility also that these cells are remnants of RPE cells attached to the photoreceptors left from the traumatic event of the RPE tear. In course of time due to lack of suitable scaffolding structures, they migrate into the retina. Individual cells might also proliferate into clumps, which are then big enough to be detected using FAF. This mechanism is however speculative.

RPE cells migrate towards various chemokines and cytokines, such as tumour necrosis factor α or interleukin 1.[@b18; @b19; @b20; @b21] After the acute event of an RPE tear, it is likely that such chemo attractants are secreted. Nevertheless, it is unclear why certain RPE cells remain in the level of Bruch\'s membrane and why others migrate into the retina. One possible explanation might be the absence of scaffolding structures, which are important for RPE cells for proliferation.

Some authors described small RPE tears where the RPE denuded area became covered by a layer of relatively normal-looking, hypopigmented RPE derived from cells from the margin of the defect.[@b22] [@b23] We also documented a case with a small RPE tear, where RPE cells migrated and covered the defect. This healing property might not be enough for large RPE tears. In 41.7% (15 eyes) of all cases, we identified a homogenous subretinal mass in the RPE denuded area. This substance may represent fibrin or proliferated RPE cells. Nevertheless, this subretinal mass failed to build a single layer, which is a prerequisite for RPE cell function in terms of ion and fluid transport.[@b24] In our study, only in 2.8% of cases RPE cells could fully cover the defect.

Animal studies of retinal pigment epithelial wound healing in rabbits[@b25] and monkeys[@b26] suggested that newly proliferated RPE cells are hypopigmented. In our study, we also saw a hypofluorescent RPE layer in FAF. We hypothesise that these new RPE cells originate from old RPE cells from tear border. But since by means of mitosis cells also give about half of their cytoplasm to the new cells, they have only about half as many lipofuscin as their original cells. Therefore, they emit less FAF signal. Although not shown in this study, it is logical to assume these new RPE cells will also accumulate lipofuscin over time as well.

There are some limitations in this study, such as the retrospective nature of the study prone to bias of uncertain kind and a relatively small number of patients. However, giving the fact that RPE tears are rare, we presented a relatively large number of patients observed. Also by combining FAF and SD-OCT we are able to observe RPE tears more efficiently.

We observed in this study 12 patients with RPE tear grade 1 or 2; however, only one patient showed self-healing mechanism. Although the exact reason is speculative, there are in vitro studies suggesting that RPE cells proliferation is dependant of age[@b27] and health of the scaffolding structure (Bruch\'s membrane).[@b28] We hypothesise that the patient with a self-healing RPE tear might have a relatively undamaged Bruch\'s membrane after the traumatic event, allowing the RPE cells to repopulate the area. Using current in vivo technologies, however, the health of Bruch\'s membrane cannot be easily assessed.

In conclusion, there is a chance that small RPE tears are populated by RPE cells, and so waiting might be appropriate. As shown previously, photoreceptors in the RPE denuded area are able to survive up to 325 days after the acute event;[@b2] we propose therefore to continue anti-vascular endothelial growth factor therapy to slow down scar progression, to protect the photoreceptors from further damage (unpublished data) and giving the chance of self-healing. In large RPE tears, however, RPE proliferation and migration might not happen in the right plain, which is under the photoreceptors. In these cases, therapies aiming at RPE layer replacement, such as in macular translocation or autologous RPE and choroid transplantation can offer help. Although we are not able to predict which patient has the greatest chance of self-healing, because only one patient in this study showed self-healing, knowing the facts that photoreceptors will survive up to 325 days[@b2] and there is a chance of self-healing of small RPE tears, we propose that therapies aiming at RPE layer replacement do not have to be performed as an emergency procedure. In fact, such risky procedures can be planned and offered, if after waiting the self-healing properties have been proven to be insufficient.
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